Literature DB >> 33099429

Stem Cell Mobilization and Autologous Transplant for Immunoglobulin Light-Chain Amyloidosis.

Morie A Gertz1, Stefan Schonland2.   

Abstract

Stem cell transplantation was one of the first proven effective regimens for the management of immunoglobulin light-chain amyloidosis. Criteria for patient selection and the mobilization regimen become important features in ensuring a safe outcome. The technique of stem cell transplantation has evolved considerably in parallel with the development of new chemotherapeutic agents for the management of amyloidosis. Optimal outcomes require both the use of effective novel agent induction and appropriate application of high-dose chemotherapy with subsequent stem cell reconstitution.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  High-dose chemotherapy; Melphalan; Mobilization; Transplantation

Year:  2020        PMID： 33099429      PMCID： PMC7594100          DOI： 10.1016/j.hoc.2020.07.007

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  37 in total

1.  Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis.

Authors:  Maria V Irazabal; Alfonso Eirin; Morie A Gertz; Angela Dispenzieri; Shaji Kumar; Francis K Buadi; Martha Q Lacy; Suzanne R Hayman; David Dingli; William J Hogan; Dennis A Gastineau; Siobhan V Glavey; Hatem Amer; Nelson Leung
Journal:  Am J Hematol       Date:  2011-11-11       Impact factor: 10.047

2.  Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function.

Authors:  M Hasib Sidiqi; Kalyan Nadiminti; Abdullah S Al Saleh; Kapil Meleveedu; Francis K Buadi; Angela Dispenzieri; Rahma Warsame; Martha Q Lacy; David Dingli; Nelson Leung; Wilson I Gonsalves; Prashant Kapoor; Taxiarchis V Kourelis; William J Hogan; Shaji K Kumar; Morie A Gertz
Journal:  Bone Marrow Transplant       Date:  2019-04-08       Impact factor: 5.483

3.  Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.

Authors:  Andrew J Cowan; Zandra K Klippel; Philip A Stevenson; Teresa S Hyun; Sherilyn Tuazon; Pamela S Becker; Damian J Green; Leona A Holmberg; David G Coffey; Ajay K Gopal; Edward N Libby
Journal:  Amyloid       Date:  2016-11-23       Impact factor: 7.141

4.  Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.

Authors:  S Taimur; C Nader; C Lloyd-Travaglini; D C Seldin; V Sanchorawala
Journal:  Transpl Infect Dis       Date:  2012-12-20       Impact factor: 2.228

5.  The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.

Authors:  Nelson Leung; Shaji K Kumar; Siobhan V Glavey; Angela Dispenzieri; Martha Q Lacy; Francis K Buadi; Suzanne R Hayman; David Dingli; Prashant Kapoor; Steven R Zeldenrust; Stephen J Russell; John A Lust; William J Hogan; S Vincent Rajkumar; Dennis A Gastineau; Taxiarchis V Kourelis; Yi Lin; Wilson I Gonsalves; Ronald S Go; Morie A Gertz
Journal:  Nephrol Dial Transplant       Date:  2015-11-30       Impact factor: 5.992

6.  Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.

Authors:  M Hasib Sidiqi; Francis K Buadi; Angela Dispenzieri; Rahma Warsame; Martha Q Lacy; David Dingli; Nelson Leung; Wilson I Gonsalves; Prashant Kapoor; Taxiarchis V Kourelis; William J Hogan; Shaji K Kumar; Morie A Gertz
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-07       Impact factor: 5.742

7.  Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis.

Authors:  Surbhi Sidana; M Hasib Sidiqi; Angela Dispenzieri; Francis K Buadi; Martha Q Lacy; Eli Muchtar; David Dingli; Suzanne R Hayman; Wilson I Gonsalves; Prashant Kapoor; Nelson Leung; Rahma Warsame; Taxiarchis V Kourelis; Robert C Wolf; William J Hogan; Shaji K Kumar; Morie A Gertz
Journal:  Am J Hematol       Date:  2019-07-11       Impact factor: 10.047

8.  Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time.

Authors:  M Hasib Sidiqi; Mohammed A Aljama; Francis K Buadi; Rahma M Warsame; Martha Q Lacy; Angela Dispenzieri; David Dingli; Wilson I Gonsalves; Shaji Kumar; Prashant Kapoor; Taxiarchis Kourelis; William J Hogan; Morie A Gertz
Journal:  J Clin Oncol       Date:  2018-03-20       Impact factor: 44.544

9.  Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation.

Authors:  Yi L Hwa; Shaji K Kumar; Morie A Gertz; Martha Q Lacy; Francis K Buadi; Taxiarchis V Kourelis; Wilson I Gonsalves; S Vincent Rajkumar; Ronald S Go; Nelson Leung; Prashant Kapoor; David Dingli; Robert A Kyle; Stephen Russell; John A Lust; Suzanne R Hayman; Yi Lin; Steven Zeldenrust; Angela Dispenzieri
Journal:  Am J Hematol       Date:  2016-07-14       Impact factor: 10.047

10.  Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.

Authors:  Aimaz Afrough; Rima M Saliba; Amir Hamdi; Medhavi Honhar; Ankur Varma; A Megan Cornelison; Gabriela Rondon; Simrit Parmar; Nina D Shah; Qaiser Bashir; Chitra Hosing; Uday Popat; Donna M Weber; Sheeba Thomas; Robert Z Orlowski; Richard E Champlin; Muzaffar H Qazilbash
Journal:  Biol Blood Marrow Transplant       Date:  2018-08-09       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.